Literature DB >> 10593636

Psychological risk factors may moderate pharmacological treatment effects among ischemic heart disease patients. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators.

T Rutledge1, W Linden, R F Davies.   

Abstract

BACKGROUND: Numerous research findings support the proposed connection between such psychological characteristics as stress and hostility and the manifestation of disease. However, less evidence is available concerning the role(s) psychological factors might play in the process of disease recovery.
METHODS: Eighty patients with known coronary disease and exercise-induced ischemia underwent treadmill exercise testing and 48-hour ambulatory electrocardiographic monitoring and completed a battery of standardized psychological tests assessing hostility, depression, and daily stress on four occasions during a 12-week pharmacological treatment study. After withdrawal of antiischemic drugs at baseline, patients returned for subsequent tests at 3-week intervals. During the second and third intervals, patients were prescribed one of two antiischemic medications, atenolol or amlodipine, or given a placebo. All patients were then placed on a combination treatment protocol for the 3 weeks before the final testing date.
RESULTS: The combination treatment produced highly significant benefits across all measured cardiac variables (20.3% improvement in exercise performance, 13% reduction in reported angina, 64.0% reduction in the frequency of ischemic episodes; for all, p < .01). However, results showed that high baseline levels of daily stress were associated with reliably smaller treatment effects on measures of ischemia frequency and treadmill exercise time and with a significantly greater likelihood of reporting angina after treatment (r = -0.24, -0.25, and -0.33, respectively; p <.05). In addition, high baseline hostility predicted significantly smaller diastolic blood pressure improvements (r = -0.29, p < .05).
CONCLUSIONS: These results indicate that psychological risk factors may have globally negative effects on the course of treatment and suggest particular factors that may warrant attention in trials targeting cardiac symptom reduction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593636     DOI: 10.1097/00006842-199911000-00018

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  5 in total

1.  Depression as a potential modulator of Beta-adrenergic-associated leukocyte mobilization in heart failure patients.

Authors:  Laura S Redwine; Petra H Wirtz; Suzi Hong; Jos A Bosch; Jos Bosch; Michael G Ziegler; Barry Greenberg; Paul J Mills
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

2.  Anxiety, depression and psychosocial stress in patients with cardiac events.

Authors:  Anne John Michael; Saroja Krishnaswamy; Tamil Selvan Muthusamy; Khalid Yusuf; Jamaludin Mohamed
Journal:  Malays J Med Sci       Date:  2005-01

3.  Leukocyte ß-adrenergic receptor sensitivity and depression severity in patients with heart failure.

Authors:  Laura S Redwine; Suzi Hong; Thomas Rutledge; Bailey Wentworth; Meredith Pung; Michael G Ziegler; Alan Maisel; Barry Greenberg; Paul J Mills
Journal:  Psychosom Med       Date:  2014 Nov-Dec       Impact factor: 4.312

4.  Adverse psychological outcome in women with coronary artery disease.

Authors:  S S Pedersen; E Boersma; C G Jansen; J W Deckers; R A M Erdman
Journal:  Neth Heart J       Date:  2001-12       Impact factor: 2.380

Review 5.  New concept for backache: biopsychosocial pain syndrome.

Authors:  Shinichi Kikuchi
Journal:  Eur Spine J       Date:  2008-11-13       Impact factor: 3.134

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.